SCHEMBL367070

SCHEMBL367070

COc1ccc(-n2/c(=N\C#N)n(C)c3cnc4ccc(-c5ccc(F)nc5F)cc4c32)cn1

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MTOR P42345 16/20 0.42
PIK3CA P42336 15/20 0.42
ATM Q13315 14/20 0.42
PIK3CD O00329 3/20 0.41
PIK3CB P42338 2/20 0.41
PIK3CG P48736 2/20 0.41
CSNK2A2 P19784 1/20 0.41
FECH P22830 1/20 0.41
CLK1 P49759 1/20 0.41
GSK3A P49840 1/20 0.41
DYRK1A Q13627 1/20 0.41
MELK Q14680 1/20 0.41
MYLK3 Q32MK0 1/20 0.41
PIK3C3 Q8NEB9 1/20 0.41
PIP4K2C Q8TBX8 1/20 0.41
TP53RK Q96S44 1/20 0.41
RPTOR Q8N122 1/20 0.39
MLST8 Q9BVC4 1/20 0.39
ATR Q13535 3/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL367071 1.00 MTOR (0.42) MTORPIK3CAATMPIK3CDPIK3CB
SCHEMBL368163 0.89 MTOR (0.41) MTORPIK3CAATMPIK3CDPIK3CB
SCHEMBL368162 0.89 MTOR (0.41) MTORPIK3CAATMPIK3CDPIK3CB
SCHEMBL14914548 0.87 MTOR (0.50) MTORPIK3CAATMPIK3CDPIK3CB
SCHEMBL14914550 0.87 MTOR (0.50) MTORPIK3CAATMPIK3CDPIK3CB
SCHEMBL368866 0.86 PIK3CA (0.45) MTORPIK3CAATMPIK3CDPIK3CB
SCHEMBL368865 0.86 PIK3CA (0.45) MTORPIK3CAATMPIK3CDPIK3CB
SCHEMBL368198 0.86 PIK3CA (0.44) MTORPIK3CAATMPIK3CDPIK3CB
SCHEMBL14913837 0.86 PIK3CA (0.44) MTORPIK3CAATMPIK3CDPIK3CB
SCHEMBL368180 0.86 PIK3CA (0.42) MTORPIK3CAATMPIK3CDPIK3CB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2593450-A1 SUBSTITUTED IMIDAZOQUINOLINE DERIVATIVES AS KINASE INHIBITORS Piramal Enterprises Limited (IN) 2013-05-22 EP claimed
US-20130116248-A1 SUBSTITUTED IMIDAZOQUINOLINE DERIVATIVES AS KINASE INHIBITORS Piramal Enterprises Limited (IN) 2013-05-09 US claimed
WO-2012007926-A1 SUBSTITUTED IMIDAZOQUINOLINE DERIVATIVES AS KINASE INHIBITORS PIRAMAL LIFE SCIENCES LIMITED (IN) 2012-01-19 WO claimed
US-9062046-B2 Substituted imidazoquinoline derivatives as kinase inhibitors Piramal Enterprises Limited (IN) 2015-06-23 US disclosed
EP-2593450-A1 SUBSTITUTED IMIDAZOQUINOLINE DERIVATIVES AS KINASE INHIBITORS Piramal Enterprises Limited (IN) 2013-05-22 EP disclosed
US-20130116248-A1 SUBSTITUTED IMIDAZOQUINOLINE DERIVATIVES AS KINASE INHIBITORS Piramal Enterprises Limited (IN) 2013-05-09 US disclosed
WO-2012007926-A1 SUBSTITUTED IMIDAZOQUINOLINE DERIVATIVES AS KINASE INHIBITORS PIRAMAL LIFE SCIENCES LIMITED (IN) 2012-01-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130116248-A1 SUBSTITUTED IMIDAZOQUINOLINE DERIVATIVES AS KINASE INHIBITORS CDK2, CDK4, MAP3K1 MTOR 102/4885PIK3CA 72/4885ATM 521/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.